Cell Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics

Jeffrey Stiltner\textsuperscript{1}, BS, Kayla McCandless\textsuperscript{1}, BS, Maliha Zahid\textsuperscript{1}, MD, PhD

1. Dept. of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Address for correspondence:

Maliha Zahid, MD, Ph.D.
Department of Developmental Biology
University of Pittsburgh School of Medicine
530 45\textsuperscript{th} St., Rangos Research Center
Pittsburgh, PA15201
Phone: 412-692-8893
Fax: 412-692-6184
Email: maz7@pitt.edu
Abstract

Since their identification over twenty-five years ago, the plethora of cell penetrating peptides (CPP) and their applications has skyrocketed. These 5 to 30 amino acid long peptides have the unique property of breaching the cell membrane barrier while carrying cargoes larger than themselves into cells in an intact, functional form. CPPs can be conjugated to fluorophores, activatable probes, radioisotopes or contrast agents for imaging tissues, such as tumors. There is no singular mechanism for translocation of CPPs into a cell, and therefore, many CPPs are taken up by a multitude of cell types, creating the challenge of tumor specific translocation and hindering clinical effectiveness. Varying strategies have been developed to combat this issue and enhance their diagnostic potential by derivatizing CPPs for better targeting by constructing specific cell activated forms. These methods are currently being used to image integrin expressing tumors, breast cancer cells, human histiocytic lymphoma and protease secreting fibrosarcoma cells, to name a few. Additionally, identifying safe, effective therapeutics for malignant tumors has long been an active area of research. CPPs can circumvent many of the complications found in treating cancer with conventional therapeutics by targeted delivery of drugs into tumors, thereby decreasing off-target side effects, a feat not achievable by currently employed conventional chemotherapeutics. Myriad types of chemotherapeutics such as tyrosine kinase inhibitors, anti-tumor antibodies and nanoparticles can be functionally attached to these peptides leading to the possibility of delivering established and novel cancer therapeutics directly to tumor tissue. While much research is needed to overcome potential issues with these peptides, they offer a significant advancement over current mechanisms to treat cancer. In this review, we present a brief overview of the research leading to identification
of CPPs with a comprehensive state of the art review on the role of these novel peptides in both cancer diagnostics as well as therapeutics.

**Key Words:** Cell penetrating peptides, protein transduction domains, tumor imaging, targeted therapies.
Introduction

As so often happens in science, the discovery of cell penetrating peptides (CPP) was a serendipitous one. Two independent groups of researchers working on the human immunodeficiency virus (HIV) viral coat Trans-activator of Transcription (Tat) protein, observed the protein’s ability to cross cell membrane barriers without any transfection reagent\(^1,2\). Similarly, the homeobox Antennapedia (Antp) transcription factor of *Drosophila melanogaster* was demonstrated to enter nerve cells in a receptor independent manner where it could then regulate neural morphogenesis \(^3\). Further mapping studies of the domains within Tat and Antp responsible for the observed transduction led to the identification of the first two CPPs: the 11 amino acid cationic, arginine and lysine rich domain of Tat protein (YGRKKRRQRRR) \(^4\) and the 16 amino acid sequence from the third helix of the Antennapedia domain (RQIKIWFQNRRMKWKK) termed Antp, also known as penetratin\(^5\). The next big development in the field of CPPs came with the demonstration of Tat peptide’s ability to cross cell membrane barriers while carrying cargo many times its size in a functional form\(^6\). Since this initial description, the plethora of CPPs has expanded exponentially. Although the first two CPPs identified were non-cell specific, researchers have utilized phage-display methodologies to identify multiple tissue-specific peptides. Phage-display was a technique developed by Smith in 1985\(^7\), and for which he subsequently received the Nobel prize for chemistry in 2018\(^8\). The technique of phage display was initially utilized to identify NRG and RGD motifs targeting tumor cells, and the utility of these peptides in delivering chemotherapeutic agents specifically to tumor vasculature was demonstrated\(^9\). Phage display has also been used to identify peptides targeting vascular endothelium \(^10\), synovial tissue \(^11\), dendritic cells \(^12\), pancreatic islet cells \(^13\) and cardiac
myocytes. And this list continues to grow every year. Hence, no one review article can do full justice to the entire breadth of CPPs, tissue and non-tissue selective, their myriad cargoes, and the number of disease conditions being tackled using them. Therefore, out of necessity, this review will be limited to tumor homing CPPs, and utility of these in tumor imaging and tumor-specific therapeutics. Interested reader is referred to several recent comprehensive reviews on other uses of CPPs.

**Cell penetrating peptides as tumor imaging agents**

CPPs are a promising tool for tumor imaging due to their high binding affinity, small size, specific uptake, high stability, rapid clearance from non-specific targets, and retention in specific targets. They can be conjugated to radioisotopes, fluorophore-labeled or activatable probes, nanoparticles (NPs), polymers, quantum dots, metal chelates, and other contrast agents in order to image tumors. CPPs are able to carry, transport, and deliver these imaging agents, providing the imaging cargo with intracellular access and functionality. Since every CPP is different and has varying chemical properties due to differences in their amino acid sequence, each faces its own challenges. An additional layer of complexity comes from the cargo it carries as that too can affect the chemical properties. Therefore, it is always important to assess the short comings of each CPP individually and when loaded with its cargo. Some challenges to using CPPs for tumor imaging include serum stability, immunogenicity, cytotoxicity, and endosomal entrapment. There is also no singular mechanism for translocation of CPPs into a cell, and therefore many CPPs are taken up by a multitude of cell types, creating the challenge of tumor specific translocation and hindering clinical effectiveness. Various strategies are currently being developed to combat these issues.
and enhance tumor diagnostic imaging. Some examples include selecting CPPs for their targeting abilities or labeling CPPs with specific cell activated constructs\textsuperscript{33,34}. One of the strategies is to select CPPs to image cancer tissues by taking advantage of overexpression of integrins by tumors, as seen in breast cancer, human histiocytic lymphoma U937, HT-1080 human fibrosarcoma cells, and SCC-7 tumors, to name a few\textsuperscript{35-37}.

Non-tumor targeting CPPs have nevertheless been used for imaging tumors. Although Tat cannot specifically target tumors, its stability in vivo and rapid translocation across cell membranes show promising abilities of peptide chelates and quantum dot conjugates as imaging agents\textsuperscript{38}. One study labeled the Tat peptide with technetium-99m (\textsuperscript{99m}Tc), one of the most common radio-isotopes for medical imaging. The peptide was synthesized using two functional domains, the first being the non-cell specific, membrane permeant portion of the Tat protein (Tat peptide), and the second domain using a peptide-based chelator for \textsuperscript{99m}Tc (ε-KGC). The [\textsuperscript{99m}Tc]-Tat-peptide combination was imaged in mice using a gamma scintillation camera and as expected, showed whole body distribution. Another study also used non-specific CPPs labeled with fluorophores instead of isotopes. The CPPs studied consisted of Tat, penetratin (Pen), octa-arginine L-enantiomer (R8). Each CPP was synthesized with a cysteine or glycyl cysteine amide and labeled with Alexa660 at the C-terminus, injected into HeLa xenograft nude mice and imaged using an IVIS Spectrum System. The accumulation of R8 in tumors was significantly higher than all other CPPs. Since the number of arginine residues affects internalization method and efficiency, and D-enantiomers decrease degradation by proteases, the L- and D-forms of the oligoarginines (2, 8, 12, and 16 mers) were repeated. The results showed the D-isoform of R8 as having the highest accumulation in tumors. This study not only
highlights CPPs as promising agents for tumor imaging, but also demonstrates how changes in peptide amino acid sequence and configuration can affect their physicochemical properties, leading to a CPP better suited to the task of imaging\textsuperscript{39}.

A separate strategy to enhance tumor targeting is by dual targeting. In this method, the CPP is conjugated with another agent to increase its targeting ability. Huang et al. synthesized linear RGERPPR (RGE) and cyclic-peptide CRGDRGPDC (cRGD) due to their demonstrated high affinity for multiple tumor cell lines. The linear RGE and cRGD was conjugated to a lipid carrier in order to enhance cell uptake and tumor targeting. The lipid carrier was embedded with the fluorescent dye DiR for tumor imaging. MDA-MB-231 breast tumor xenograft mouse models were injected with the conjugate and imaged using a near-infrared fluorescence imaging system. The linear RGE conjugate showed the highest uptake and retention in tumors, making RGE and the CPP-NP combination promising tools for tumor imaging\textsuperscript{40}. Another study used CPP and NP dual targeting combination to target tumor cells, but with the addition of another imaging agent for dual-modality imaging (photoacoustic (PA) and MRI imaging). In this study, the CPP, F3 peptide, and NP, poly(lactic-co-glycolic acid) (PLGA), were used for their cell targeting and penetrating abilities respectively. The sonosensitizer, methylene blue, was embedded with Gd-DTPA-BMA in PLGA to combine the new promising imaging modality, PA, with the current clinical imaging modality MRI. MDA-MB-231 tumor-bearing mice were injected with the synthesized F3-PLGA@MB/Gd NP and evaluated using dual-imaging. The results showed F3-PLGA@MB/Gd NP had the highest concentration in tumors compared to the non-targeted groups in both PA and MRI, most notably at 6 hrs. post-injection. Again, this study highlights a promising CPP (F3) and CPP-NP combination for tumor imaging, demonstrating that
there are multiple variations of CPPs and combinations with CPPs that can be used to advance tumor imaging\textsuperscript{41}.

Another strategy to enhance tumor imaging is via use of activatable CPPs (ACPPs). In this method, the CPP contains a region which can penetrate cells and carry cargo (polycation), a region which can target metalloproteases-2 (MMP-2) and MMP-9 (protease-cleavable linker), and a region which quenches the function of the cell penetrating region (polyanion). When activated by MMP-2 and MMP-9, the neutralizing region is cleaved and the CPP can enter the cell. Since MMP-2 and MMP-9 are over expressed in many cancer lines, the hypothesis was that ACPPs will target tumors preferentially than non-tumor tissues. A recent study used an ACPP labeled with Cy5 to target and image colorectal cancer. In vivo and ex vivo fluorescent imaging was performed using an IVIS imaging system in HCT-116 xenograft nude mice. The results showed that ACPP-Cy5 accumulated in tumors, liver metastases, and kidneys, making it a promising imaging agent for detecting tumors and metastases\textsuperscript{42}. Specific cargo can also be attached to ACPPs to enhance tumor targeting and imaging abilities. Macromolecules can increase circulation time and tumor uptake, decrease background noise through less glomerular and synovial filtration, amplify the amount of imaging agent on a single peptide, decrease toxicity, and allow for multi-modality imaging. Olson et al. conjugated polyamidoamine dendrimer to the polycationic domain of an ACPP. They used Cy5 and Gd chelates to dual label the ACPP dendrimer combination for fluorescent and MRI imaging in tumor-bearing mice. The results showed better uptake and tumor specificity than previously reported results, once again illustrating the myriad ways in which CPPs can be altered and combined to improve tumor imaging\textsuperscript{43}. 
Cell penetrating peptides as vectors for targeted drug delivery to tumors

Cancer is a leading cause of mortality globally, second only to cardiovascular diseases\(^4^4\). In 2017 cancer claimed the lives of nearly 10 million people worldwide\(^4^4\). As the average life expectancy, standard of living and access to healthcare increase, people are living longer lives with consequently a shift in mortality rates from infectious diseases\(^4^5\) and rise in cancer related mortality that is predicted to continue to increase globally over the coming decades. Despite advancements in oncological research and medicine, conventional chemotherapeutics still have many limitations and deficiencies. One example is doxorubicin, a common chemotherapeutic agent, which suffers from poor tumor penetration\(^4^6\). This poor penetration translates into deeper areas of the tumor not receiving adequate drug concentrations allowing cancer cells to remain viable and continue to mutate and proliferate\(^4^6\). A second issue is the high interstitial pressure present in tumors which blocks efficient delivery of drugs through transcapillary transport\(^4^7,4^8\). This elevated interstitial pressure causes a radially outward pressure away from the tumor, making access by chemotherapeutics through simple diffusion challenging\(^4^8\).

Another issue is development of tumor resistance to chemotherapy over time\(^4^9\), the mechanism of which is not well understood, but is thought to involve cancer stem cells playing a role, leading to tumor relapses\(^5^0\). Another issue with modern cancer drugs are the large doses needed due to lack of targeting specificity\(^5^1,5^2\), which contributes substantially to toxicity and side effects making chemotherapy poorly tolerated by patients\(^5^3\).

Cell penetrating peptides have shown great preclinical and clinical evidence for overcoming many of the shortfalls of conventional chemotherapeutics. Multiple drugs have been attached to cell-penetrating peptides in pre-clinical research in an attempt to target
tumors. Five classes in particular have shown great promise: conventional chemotherapeutics, pro-apoptotic peptides/proteins, NP formulated peptides, anti-tumor antibodies and siRNA. Co-administration of a cell penetrating peptide with a tumor targeting drug allowed the drug to penetrate into tumor’s extravascular space in a tumor-specific and neuropilin-1 dependent manner\textsuperscript{54}. Interestingly enough, peptide coadministration with a wide variety of tumor targeting drugs, such as small molecule chemotherapeutics, NPs, and monoclonal antibodies, have all had their therapeutic indices increased as a result of this coadministration\textsuperscript{54-56}. Thus, the increased tissue permeability seen with these tumor targeting drugs co-administered with cell penetrating peptides is a viable strategy for overcoming the poor penetration of currently available chemotherapeutics.

Another promising area of development in cell penetrating peptides is their apparent ability to overcome drug resistance issues previously seen with modern anti-cancer drugs. In one study the peptide iRGD was administered with nab-paclitaxel, an albumin-bound form of paclitaxel, led to effective treatment of a previously resistant breast cancer xenograft\textsuperscript{54}. While an exact mechanism by which CPP co-administration reduces drug resistance is unknown, it is hypothesized that co-administration could result in drugs entering via endocytosis rather than by classical mechanisms through the cell membrane, resulting in a greater amount of cellular uptake of the chemotherapeutic\textsuperscript{49,57}. Furthermore, due to the excellent targeting and transduction of drugs attached to CPPs, lower systemic drug dose can be used so that the body’s natural mechanisms that induce resistant are less of a factor\textsuperscript{58}. Modern anti-cancer chemotherapeutics lack targeting specificity which often results in side effects such as nausea, insomnia, bone marrow depression, fatigue, weakness, and many other adverse effects\textsuperscript{59}. All
malignant tumor masses contain certain molecular markers that are not expressed in normal
cells or are expressed at significantly lower rates\(^6^0\). Receptors such as IL-11R\(\alpha\), GRP78, EphA5
have been found to be differentially overexpressed in tumor cells and thus make attractive
candidates for targeting\(^6^1,6^2\). By coupling an anti-cancer drug to a targeting ligand for these
receptors, the drug can effectively accumulate in the tumor leading to greater therapeutic
effect and fewer side effects\(^6^0-6^2\).

Remarkably, recent research suggest drug delivery with cell-penetrating peptides may
also occur via a second general mechanism known as the bystander-effect\(^6^3\). This pathway
allows for co-administration of a drug payload without the drug actually being covalently
attached to the cell-penetrating peptide\(^6^3,3^2\). The pathway involved in this bystander effect is
known as the C-end Rule pathway which is endocytic transport pathway related to but distinct
from micropinocytosis\(^6^3\). The peptide that activates this pathway is known as iRGD\(^6^3\). This
peptide binds to a tumor-specific receptor after which it is proteolytically cleaved and then
binds to a second receptor, neuropilin-1, resulting in activation of the CendR pathway\(^6^3\). The
endocytic vesicles that are formed in the CendR pathway are big and can contain and transport
a large amount of extracellular fluid\(^6^3\), including chemotherapeutic drugs present in the
interstitium. This phenomenon of the CendR pathway explains why certain peptides can
transport drug payloads that are simply co-administered with the peptide and not necessarily
covalently attached to the peptide. Many pre-clinical trials have utilized iRGD and the CendR
pathways to deliver anti-cancer drugs. In one study a wide variety of anti-cancer drugs were co-
administered with iRGD and all saw an increase in their therapeutic indices\(^5^4\). In another study
the anti-cancer effects of gemcitabine were enhanced in a murine pancreatic cancer model that
overexpressed neuropilin-1 when co-administered with iRGD. Similar results have been seen in studies examining gastric cancers and hepatocellular carcinoma. These successful preclinical trials that co-administered anti-cancer drugs with iRGD validate the CendR pathway and provide strong basis for future clinical research.

Conventional chemotherapeutics have shown promise when attached to cell-penetrating peptides. Paclitaxel is a widely used chemotherapeutic. Paclitaxel can stop mitosis and cause cell death by binding to microtubules. As mentioned earlier many conventional chemotherapeutics, such as paclitaxel, have issues such as poor solubility, toxicity and acquired resistance. Conjugating Paclitaxel to various cell-penetrating peptides has proven to be advantageous in minimizing these negative aspects and maximizing therapeutic effects. Of particular interest is the recent work in attaching octa-arginine to the C2’ position of paclitaxel via a disulfide linker. When attached to octa-arginine, paclitaxel was able to overcome drug resistance, and increased solubility. In mice with ovarian cancer the octa-arginine-paclitaxel conjugate had a 4.8 fold higher therapeutic response compared with paclitaxel alone. Another commonly used chemotherapeutic, doxorubicin, has also shown promising results when attached to a CPP. Doxorubicin is a topoisomerase II inhibitor that has been used clinically to treat many types of cancer, but faces many of the same issues as paclitaxel. Doxorubicin has an intrinsic P-glycoprotein overexpression which makes it particularly difficult to get effective therapeutic tumoral concentrations and can cause resistance. In one study a Tat-doxorubicin conjugate was designed, and administered to resistant KB-V1 tumor cells. The results showed 86% of tumor cell cytotoxicity with the Tat-doxorubicin conjugate versus only 14% with doxorubicin alone.
Pro-apoptotic proteins have also shown pre-clinical promise when attached to CPPs particularly p53\textsuperscript{76-78}. 11 poly-arginine peptides (11R) have also been shown to suppress the proliferation of oral cancer\textsuperscript{76}. The conjugate 11R-p53 suppressed activity of the p21/WAF promoter thus stopping the proliferation of cancer cells\textsuperscript{76}. Further studies have shown that linking the polyarginine-p53 fusion protein to the NH2-terminal of a modified influence virus subunit was able to inhibit the proliferation of bladder cancer\textsuperscript{77,78}. Thus p53 as a pro-apoptotic protein has shown great promise when attached to CPPs leading to halting proliferation of many different types of cancer cells.

Monoclonal antibodies have long been used in medicine particularly in immunotherapy. However, one of the main concerns with using monoclonal antibodies in oncology has been the issues with cell penetration due to their large size (150 kDa)\textsuperscript{79}. By attaching these anti-tumor antibodies to CPPs, studies have shown promise in overcoming this cell membrane barrier. The cell penetrating anti-body 3E10 recognizes and physically binds to the N-terminus of RAD51 subsequently sequestering it in the cytoplasm and preventing it from binding to DNA and causing damage leading to cancer\textsuperscript{79}. Another cell-penetrating antibody, RT11, has been shown to be internalized and selectively bind to activated GTP-bound form of oncogenic Ras mutants which blocks downstream signaling of these mutants and prevents the proliferation of tumor cells\textsuperscript{80}. Other research has shown great promise in designing cell-penetrating anti-bodies with high cell-specificity and high endosomal escape efficacy such as epCT65 which has great potential for medical applications such as cystolic delivery of drug payloads to tumors\textsuperscript{80}. There are currently 12 FDA approved anti-bodies used for treating cancer and despite their promise in
preclinical research when attached to CPP there are still issues with them such as solubility and intracellular stability$^{78}$. Antibodies formulated with CPPs into nanoparticles (NPs) are another promising strategy since they have increased solubility and intracellular stability compared to antibodies alone$^{79,81}$. CapG is part of the actin filament, often overexpressed in breast cancer, and is believed to play a role in tumor cell metastasis$^{82}$. Attaching a nanoparticle that works against CapG to various CPPs has been shown to be an effective strategy in reducing breast cancer metastasis$^{81,82}$. More recent research suggests that just the presence of NPs in addition to a CPP and anti-tumor drug enhances the effect of the latter$^{83}$. One study showed that the delivery of a pro-apoptotic drug as part of a NP-CPP system increased anti-tumor activity by a factor of 100-300$^{83}$. This system has shown incredible promise in treating glioblastoma in preclinical research$^{83}$. Interestingly enough, attaching the CPP iRGD to NPs increased its anti-metastatic activity as compared to when it is just used as a soluble peptide$^{78,84}$.

Small interfering RNA (siRNA) is noncoding RNA that stops the expression of certain genes by degrading mRNA created during translation; this ultimately prevents ribosomes from translating the mRNAs into functional proteins$^{85-89}$. SiRNAs shows great potential at treating cancer; however, their adaption in clinical settings has been slow due to a lack of safe and effective vehicle for delivery.$^{85}$ Cell-penetrating peptides show promise in pre-clinical research to be safe and effective vehicles for siRNA to target tumors. Many peptides, such as CPP33, gh625, PD-L1, PEG-SS-PEI and many others, have been used in combination with siRNA to target various forms of cancer to great success in animal models$^{85-89}$. Not only did these peptides coupled to siRNA increase the ability to enter tumor cells, but they helped aid in endosomal
escape of the siRNAs once they were internalized into cells\textsuperscript{85-89}. CPP33 loaded with siPLK1 (an siRNA to target A549 lung cancer cells) exhibited additional endosomal escape but also prolonged blood circulation, enhanced tumor accumulation and effective suppression of tumor growth\textsuperscript{85}. Additionally, coupling siRNA to cell-penetrating peptides reduced the concentration of siRNA required to achieve reduction in tumor size\textsuperscript{88}. These cell penetrating-peptide and siRNA payloads have shown to exhibit enhanced antitumor effects in multiple types of cancer in mice including lung, breast and liver cancers\textsuperscript{85-89}. Thus, conjugating siRNAs to peptides offer another promising avenue in clinical research for the overall treatment of cancer.

**Clinical Trials Using CPPs as Cancer Therapeutics**

The authors currently know of ten clinical trials involving CPPs to treat cancer. This number is expected to increase as additional advancements are made to CPPs in the arena of cancer therapeutics. Of the ten clinical trials discussed in the table below (Table 1), 6 have completed at least Phase 1a and are continuing onto phase 1b and phase 2; the other 4 are in the process of recruiting and completing phase 1. Aileron therapeutics seems to be a leader in innovation with their ALRN-6924 peptide that is being successfully employed in half of the clinical studies discussed below. ALRN-6924 is a CPP that disrupts interaction between p53 tumor suppressor protein and its inhibitors MDMX and MDM2\textsuperscript{90-94}. This peptide has been tested alone for safety and efficacy as well as combined to many anti-cancer drugs such as cytarabine, paclitaxel and topotecan\textsuperscript{90-94}. Phase 1 clinical trials have shown that ALRN-6924 alone and in combination is safe and increases the therapeutic index of the covalently attached drugs\textsuperscript{90-94}. ALRN-6924 is currently being employed in two clinical trials that are in phase 2 and have shown promising results in cancer treatment including pediatric cases\textsuperscript{93,94}. Another
peptide currently in clinical trial is BT1718, designed to target and inhibit the function of MT1-MMP by recognizing and attaching itself to the MT1-MMP protein. Once it is attached it is internalized into cancer cells. P28 is another CPP being evaluated currently in two cancer clinical trials. It is derived from azurin and targets solid tumors that resist standard methods of treatment. Both of these trials have completed phase 1 and look promising at treating solid tumors resistant to conventional chemotherapeutics. PEP-010 is another peptide about to begin enrollment into a Phase I trial to assess its safety profile.

Since their identification nearly twenty-five years ago, the number and applications of CPPs, both in the arena of tumor diagnostics and therapeutics, continues to grow at a brisk pace. Combining them as novel vectors for targeted delivery of both established and emerging therapeutics has the potential to reduce drug doses, decrease tumor resistance and reduce off-target adverse effects that so often limit dosage of chemotherapeutics, as well as adversely affect patient quality of life.

Disclosures: The authors list no disclosures, nor relationships with industry in relationship to the presented work.

Funding: All authors are supported by an R01 grant HL153407 from the NHLBI awarded to MZ.
Table 1: Summary of various clinical trials utilizing CPPs in anti-cancer therapies.

| Sponsor                  | ClinicalTrials.gov Identifier | Study Stage                      | CPP Employed | Cancer-Targeted                                                                 | Drug Employed with CPP                                                                 | Study Size |
|--------------------------|-------------------------------|----------------------------------|--------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------|
| Aileron Therapeutics⁹⁰   | NCT02264613                   | Phase 1-Completed, Phase 2a-Completed | ALRN-6924    | Solid Tumor, Lymphoma, and Peripheral T-Cell Lymphoma                         | ALRN-6924 Tested alone and in combination with palbociclib                              | 149        |
| Aileron Therapeutics⁹¹   | NCT02909972                   | Phase 1-Completed                | ALRN-6924    | Acute Myeloid Leukemia, and Advanced Myelodysplastic Syndrome                 | ALRN-6924 Tested alone and in combination with Cytarabine                              | 55         |
| Aileron Therapeutics⁹²   | NCT03725436                   | Phase 1                          | ALRN-6924    | Advanced, Metastatic or unresectable solid tumors                             | ALRN-6924 in combination with paclitaxel                                               | 45         |
| Aileron Therapeutics⁹³   | NCT03654716                   | Phase 1                          | ALRN-6924    | Pediatric Leukemia, Pediatric Brain tumor, pediatric Solid Tumor, Pediatric Lymphoma | ALRN-6924 alone or in combination with cytarabine for patients with leukemia           | 69         |
| Aileron Therapeutics⁹⁴   | NCT04022876                   | Phase 1a-Completed, Phase 1b, Phase 2 | ALRN-6924    | Small Cell Lung Cancer                                                        | Phase 1b-ALRN-6924 with Topotecan Phase 2-Topotecan alone and with ALRN-6924           | 120        |
| Cancer Research UK⁹⁵     | NCT03486730                   | Phase 1, Phase 2                 | BT1718       | Advanced Solid Tumors, Non-small cell lung cancer, Non-                         | BT1718 Alone                                                                          | 130        |
| Institution                                                                 | Trial ID         | Phase | Treatment                                                                 | Study Type | Patients |
|----------------------------------------------------------------------------|-----------------|-------|---------------------------------------------------------------------------|------------|----------|
| CDG Therapeutics and Dr. Tapas K. Das Gupta                            | NCT00914914     | Phase 1-Completed | P28 Refractory Solid Tumors                                              | Completed  | 15       |
| Pediatric Brain Tumor Consortium/ National Cancer Institute (NCI)         | NCT01975116     | Phase 1-Completed | P28 Recurrent or Progressive Central Nervous System Tumors              | Completed  | 18       |
| Institut Curie                                                           | NCT04733027     | Phase 1 | PEP-010 Metastatic Solid Tumor Cancer                                      |            | 56       |
| Amal Therapeutics                                                        | NCT04046445     | Phase 1a-Completed Phase 1b ATP128 Stage IV Colorectal Cancer           |            | 32       |
References

1. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-93.
2. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988;55:1179-88.
3. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 1991;88:1864-8.
4. Green M, Ishino M, Loewenstein PM. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 1989;58:215-23.
5. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269:10444-50.
6. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
7. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-7.
8. Smith GP. Phage Display: Simple Evolution in a Petri Dish (Nobel Lecture). Angew Chem Int Ed Engl 2019;58:14428-37.
9. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
10. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000;102:231-7.
11. Mi Z, Lu X, Mai JC, et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 2003;8:295-305.
12. Chamarthy SP, Jia L, Kovacs JR, et al. Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. Molecular immunology 2004;41:741-9.
13. Rehman KK, Bertera S, Bottino R, et al. Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. The Journal of biological chemistry 2003;278:9862-8.
14. Zahid M, Phillips BE, Albers SM, Giannoukakis N, Watkins SC, Robbins PD. Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice. PLoS One 2010;5:e12252.
15. Taylor RE, Zahid M. Cell Penetrating Peptides, Novel Vectors for Gene Therapy. Pharmaceutics 2020;12.
16. Zahid M, Robbins PD. Cell-type specific penetrating peptides: therapeutic promises and challenges. Molecules 2015;20:13055-70.
17. Alves ID, Bechara C, Walrnt A, Zaltsman Y, Jiao CY, Sagan S. Relationships between membrane binding, affinity and cell internalization efficacy of a cell-penetrating peptide: penetratin as a case study. PLoS One 2011;6:e24096.
18. Ward B, Seal BL, Brophy CM, Panitch A. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J Pept Sci 2009;15:668-74.
19. Rennert R, Wespe C, Beck-Sickinger AG, Neundorf I. Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochim Biophys Acta 2006;1758:347-54.
20. Neundorf I, Rennert R, Franke J, Kozle I, Bergmann R. Detailed analysis concerning the biodistribution and metabolism of human calcitonin-derived cell-penetrating peptides. Bioconjug Chem 2008;19:1596-603.
21. Lindgren ME, Hallbrink MM, Elmquist AM, Langel U. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J 2004;377:69-76.
22. Santra S, Yang H, Stanley JT, et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem Commun (Camb) 2005:3144-6.
23. Medintz IL, Pons T, Delehanty JB, et al. Intracellular delivery of quantum dot-protein cargos mediated by cell penetrating peptides. Bioconjug Chem 2008;19:1785-95.
24. Zhang K, Fang H, Chen Z, Taylor JS, Wooley KL. Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. Bioconjug Chem 2008;19:1880-7.
25. Bohmova E, Pola R, Pechar M, et al. Polymer Cancerostatics Containing Cell-Penetrating Peptides: Internalization Efficacy Depends on Peptide Type and Spacer Length. Pharmaceutics 2020;12.
26. Boonyarattanakalin S, Athavankar S, Sun Q, Peterson BR. Synthesis of an artificial cell surface receptor that enables oligohistidine affinity tags to function as metal-dependent cell-penetrating peptides. J Am Chem Soc 2006;128:386-7.
27. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem 2009;284:33957-65.
28. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001;1515:101-9.
29. Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 2007;18:50-60.
30. Mager I, Eiriksdottir E, Langel K, El Andaloussi S, Langel U. Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochim Biophys Acta 2010;1798:338-43.
31. Suhorutsenko J, Oskolkov N, Arukuusk P, et al. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem 2011;22:2255-62.
32. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-90.
33. Sauter M, Strieker M, Kleist C, et al. Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. J Control Release 2020;322:200-8.
34. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004;101:17867-72.
35. Shi NQ, Gao W, Xiang B, Qi XR. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine 2012;7:1613-21.
36. Kolesinska B, Eyer K, Robinson T, et al. Interaction of beta(3) /beta(2) -peptides, consisting of Val-Ala-Leu segments, with POPC giant unilamellar vesicles (GUVs) and white blood cancer cells (U937)--a new type of cell-penetrating peptides, and a surprising chain-length dependence of their vesicle- and cell-lysing activity. Chem Biodivers 2015;12:697-732.
37. Qiu WX, Liu LH, Li SY, Lei Q, Luo GF, Zhang XZ. ACPI Conjugated Gold Nanorods as Nanoplatform for Dual Image Guided Activatable Photodynamic and Photothermal Combined Therapy In Vivo. Small 2017;13.
38. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 2000;11:762-71.
39. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release 2012;159:181-8.
40. Huang R, Li J, Kebebe D, Wu Y, Zhang B, Liu Z. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment. Drug Deliv 2018;25:757-65.
41. Li Y, Hao L, Liu F, et al. Cell penetrating peptide-modified nanoparticles for tumor targeted imaging and synergistic effect of sonodynamic/HIFU therapy. Int J Nanomedicine 2019;14:5875-94.
42. Zeng Z, Chen J, Luo S, et al. Targeting and imaging colorectal cancer by activatable cell-penetrating peptides. Am J Transl Res 2020;12:1754-66.
43. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010;107:4311-6.
44. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-210.
45. Ryerson AB, Eheman CR, Altekuruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312-37.
46. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005;11:8782-8.
47. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
48. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
49. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 2009;10:836-41.
50. Zhao J. Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther 2016;160:145-58.
51. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target 2008;16:108-23.
52. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-6.
53. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
54. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.
55. Khawli LA, Hu P, Epstein AL. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res 2005;11:3084-93.
56. Kinoshita R, Ishima Y, Chuang VTG, et al. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Biomaterials 2017;140:162-9.
57. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10:73-9.
58. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010;624:25-37.
59. Colagiuri B, Dhillon H, Butow PN, Jansen J, Cox K, Jacquet J. Does assessing patients’ expectancies about chemotherapy side effects influence their occurrence? J Pain Symptom Manage 2013;46:275-81.
60. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010;188:759-68.
61. Yao VJ, D’Angelo S, Butler KS, et al. Ligand-targeted theranostic nanomedicines against cancer. J Control Release 2016;240:267-86.
62. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 2012;24:3747-56.
63. Ruoslahti E. Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev 2017;110-111:3-12.
64. Akashi Y, Oda T, Ohara Y, et al. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Br J Cancer 2014;110:1481-7.
65. Sha H, Zou Z, Xin K, et al. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release 2015;200:188-200.
66. Schmithals C, Koberle V, Korkusuz H, et al. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. Cancer Res 2015;75:3147-54.
67. Chipman SD, Oldham FB, Pezzeni G, Singer JW. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine 2006;1:375-83.
68. Gao Y, Kuang Y, Guo ZF, Guo Z, Krauss IJ, Xu B. Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative. J Am Chem Soc 2009;131:13576-7.
69. Tong R, Cheng J. Drug-Initiated, Controlled Ring-Opening Polymerization for the Synthesis of Polymer-Drug Conjugates. Macromolecules 2012;45:2225-32.
70. Yin Y, Wu X, Yang Z, et al. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res 2013;30:2050-62.
71. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci U S A 2008;105:12128-33.

72. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intraarterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-7.

73. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.

74. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.

75. Zhang P, Cheetham AG, Lock LL, Cui H. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem 2013;24:604-13.

76. Takenobu T, Tomizawa K, Matsushita M, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002;1:1043-9.

77. Michiue H, Tomizawa K, Wei FY, et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 2005;280:8285-9.

78. Jauet T, Beaulieu ME. Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead. Curr Opin Pharmacol 2019;47:133-40.

79. Turchick A, Hegan DC, Jensen RB, Glazer PM. A cell-penetrating antibody inhibits human RAD51 via direct binding. Nucleic Acids Res 2017;45:11782-99.

80. Shin SM, Choi DK, Jung K, et al. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Nat Commun 2017;8:15090.

81. Van Impe K, Bethuyne J, Cool S, et al. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res 2013;15:R116.

82. Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A 2011;108:17450-5.

83. Hamilton AM, Aidoudi-Ahmed S, Sharma S, et al. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J Mol Med (Berl) 2015;93:991-1001.

84. Sugahara KN, Braun GB, de Mendoza TH, et al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol Cancer Ther 2015;14:120-8.

85. Qiu M, Ouyang J, Wei Y, et al. Selective Cell Penetrating Peptide-Functionalized Envelope-Type Chimeric Lipopepsomes Boost Systemic RNAi Therapy for Lung Tumors. Adv Healthc Mater 2019;8(16):e1900500.

86. Ben Djemaa S, Hervé-Aubert K, Lajoie L, et al. gh625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line. Biomacromolecules 2019;20(8):3076-3086.

87. Li G, Gao Y, Gong C, et al. Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle. ACS Appl Mater Interfaces 2019;11(43):39513-39524.
88. Furukawa K, Tanaka M, Oba M. siRNA delivery using amphipathic cell-penetrating peptides into human hepatoma cells. Bioorg Med Chem 2020;28(8):115402.
89. Zhang C, Yuan W, Wu Y, et al. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells. Life Sci 2021;266:118886.
90. Aileron Therapeutics. ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas. Clinicaltrials.gov 2014; NCT02264613 (ClinicalTrials.gov Identifier).
91. Aileron Therapeutics. Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome. Clinicaltrials.gov 2016; NCT02909972 (ClinicalTrials.gov Identifier).
92. Aileron Therapeutics. ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors. Clinicaltrials.gov 2018; NCT03725436 (ClinicalTrials.gov Identifier).
93. Aileron Therapeutics. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer. Clinicaltrials.gov 2018; NCT03654716 (ClinicalTrials.gov Identifier).
94. Aileron Therapeutics. A Study of ALRN-6924 for the Prevention of Topotecan-induced Myelosuppression During Treatment for Small Cell Lung Cancer. Clinicaltrials.gov 2019; NCT04022876 (ClinicalTrials.gov Identifier).
95. Cancer Research UK. BT1718 in Patients With Advanced Solid Tumours. Clinicaltrials.gov 2018; NCT03486730 (ClinicalTrials.gov Identifier).
96. Das Gupta TK. Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment. Clinicaltrials.gov 2009; NCT00914914 (ClinicalTrials.gov Identifier).
97. Pediatric Brain Tumor Consortium. p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors. Clinicaltrials.gov 2013; NCT01975116 (ClinicalTrials.gov Identifier).
98. Institut Curie. First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel (CleverPeptide). Clinicaltrials.gov 2021; NCT04733027 (ClinicalTrials.gov Identifier).
99. Amal Therapeutics. Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01). Clinicaltrials.gov 2019; NCT04046445 (ClinicalTrials.gov Identifier).